What a glioma second opinion can and cannot settle from records
A records-based opinion is a review of material you already have. For a glioma, that usually means a neurosurgeon, neuro-oncologist or radiation oncologist reading your imaging and pathology alongside your treatment history and telling you what they would consider next, what they would want clarified, and where their view differs from the plan you have been offered. It is a clinical opinion about the evidence in front of them.
It is not the same as hospital acceptance, a surgical plan, or a final decision on eligibility for any particular treatment. Those depend on the treating hospital seeing the patient, confirming the histology and molecular profile, and making its own assessment. A remote review can flag that a pathology block needs re-cutting or that a scan sequence is missing, but it cannot replace the tests the receiving team decides are necessary.
This distinction matters when you are deciding whether to travel. A second opinion may help you judge whether the proposed approach is reasonable, whether another option deserves discussion, and what questions to put to your current team. It does not guarantee that any treatment will be available in China, and it does not establish eligibility for a clinical trial or an advanced therapy.
One practical consequence: send records that let the reviewer answer your actual question. If you want to know whether surgery is still worth considering, the reviewer needs the operative note and the post-operative imaging, not only the first scan. If you want to know whether the pathology classification is secure, the reviewer needs the report and, where possible, the material behind it.
Imaging: the sequences that carry the decision
Glioma assessment rests heavily on MRI, and the value of a second opinion depends on receiving the actual images rather than the radiologist's report alone. A report summarises; the reviewer needs to see the tumour, its margins, its relationship to eloquent cortex and white-matter tracts, and how it has changed over time.
Ask your imaging centre for the full study on disc or through a secure transfer link, in DICOM format, including the sequences acquired. For brain tumour work this generally includes pre- and post-contrast T1-weighted images, T2-weighted and FLAIR images, and diffusion-weighted imaging. If perfusion, spectroscopy or tractography were performed, include those too. The reviewer can tell you whether something essential is absent, but only if the request reaches them before the review.
A dated list of every scan, with the date, hospital and body region, saves the reviewer from reconstructing your timeline. Note which scan followed surgery and which followed radiotherapy, because post-treatment changes can be difficult to interpret without that context. If your hospital can export a radiology report in English, include it; if not, ask whether the receiving team can work with the original language and arrange interpretation.
Do not assume that older imaging is irrelevant. A baseline scan before any treatment often helps the reviewer understand the tumour's natural behaviour and the effect of what followed. Send the earliest diagnostic study you have as well as the most recent.
Pathology and molecular reports: the tissue evidence
The pathology report is central. For gliomas, modern classification depends on both the microscopic appearance and molecular markers, so the report you send should be the full version, not a one-line summary. Look for the integrated diagnosis, the tumour grade, and the molecular results your hospital recorded, such as IDH mutation status, 1p/19q codeletion status and MGMT promoter methylation where tested. Which markers were run varies between laboratories and over time; the reviewer will tell you what is missing for their purposes.
If a second opinion might hinge on the tissue diagnosis, ask your hospital whether slides or a paraffin block can be released for review. Some centres will re-review outside material; others will ask for a fresh section. The mechanics differ by hospital and by country, so confirm with your treating hospital what it will release and with the receiving team what it will accept. Do not send irreplaceable blocks without agreeing the return arrangements in writing.
Include the original surgical pathology report and any later reports, for example from a repeat resection. If molecular testing was done at a separate laboratory, send that report too, with the specimen it refers to. A reviewer comparing an early report with a later one needs to know which specimen each describes.
Where a report is in another language, ask the receiving team whether a certified translation is required or whether a working translation is enough for an initial opinion. This is an administrative question for that team, not something to guess.
Treatment history: a dated summary the reviewer can follow
Write a short chronological summary yourself, even if your hospital also provides records. Include the date of first symptoms or first scan, the date and type of any surgery with the operative note, the histology result, any radiotherapy with the dose and target described in your records, and any chemotherapy with the agents and dates. Add any other treatment, including trials, and any significant complications.
Attach the supporting documents behind that summary: discharge summaries, operation notes, radiotherapy plans and completion summaries, and clinic letters that record decisions and their reasons. If a treatment was stopped early or changed, note why, because the reason often shapes what a reviewer would suggest next.
Include a current medication list and a note of relevant other conditions, allergies and any implanted device. These affect what a treating team can offer and what it must check before any procedure. Do not send a complete lifetime medical archive; send what bears on the glioma decision and say what else is available on request.
Finally, state your question in two or three sentences. "Is further surgery reasonable now?" and "Was the molecular work-up adequate to guide treatment?" lead to different reviews. A clear question helps the team decide which specialties should look at the file.
How to send records without losing control of them
Start with a brief summary rather than a full archive. ChinaSpecialistCare's free initial case review checks the available diagnosis, records and your main question, identifies missing information and suggests a relevant next step. It is not a diagnosis and not a promise of acceptance. You can begin through the enquiry form, email or WhatsApp with a short description, and share fuller records once the team has told you what is useful.
For the records themselves, use a secure transfer method rather than ordinary email attachments for large imaging files. Label every file with the date and document type so the reviewer can match it to your summary. Keep your own copy of everything you send, and keep a list of what was sent, to whom and when.
If you are considering a formal records-based opinion from a hospital specialist while you remain at home, ChinaSpecialistCare's optional proxy consultation is one route; current service fees are set out on the care-review page, and a proxy consultation is optional rather than a prerequisite for every appointment or operation. Hospital consultation fees are separate from coordination fees. For a complex case spanning neurosurgery, neuro-oncology and radiation oncology, a multidisciplinary review involving two or three relevant specialties may be arranged, with the scope and fee agreed first.
Ask the receiving team, in writing, what its opinion will cover, which records it will review, whether it will comment on the pathology material directly, and what it will not be able to conclude without seeing the patient. That written scope is more useful than an assumption about what a second opinion includes.
Questions to put to the reviewing team, and the next step
Before the review, decide what you want from it. Useful questions include: does the imaging show anything that changes the surgical picture; is the pathology classification and molecular work-up complete enough to guide treatment; what would this team want to confirm in person; and which of the options under discussion would it consider reasonable, and why. Ask also how the opinion will be delivered and whether it will address your current team's plan directly.
Expect the review to name limits. A reviewer working from records may say that a scan needs repeating, that a pathology block should be re-examined, or that a decision requires an in-person assessment. Those are legitimate outcomes, not failures of the process. Treat them as the questions to resolve next with your treating clinicians.
Urgent or worsening symptoms, such as new weakness, seizures or severe headache, need local assessment rather than an overseas records review. Do not delay that care to assemble a file.
If you want to proceed, send a short summary of the diagnosis, the treatment so far and your main question through the enquiry form, email or WhatsApp. The team will tell you what else is useful and whether a records-based opinion or an appointment route fits your question. The initial enquiry is free, and the hospital, not the coordinator, decides clinical suitability.
Sources & scope of this guide
References and official service information relevant to this guide.
- radiotherapy
- neurosurgery
- Related treatment reference
- Overview | Brain tumours (primary) and brain metastases in over 16s | Guidance | NICE
- Childhood Glioma (Including Astrocytoma) - NCI
- Adult Central Nervous System Tumors Treatment - NCI
- Childhood Medulloblastoma & Other CNS Embryonal Tumors Treatment - NCI
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
